OrbiMed Co-leads $20M Series A Round In Zentera Therapeutics

Zentera Therapeutics, a Shanghai-based biopharmaceutical company, has completed a US$20 million Series A round financing led by Tybourne Capital Management and OrbiMed Asia. Zentalis, through its wholly owned subsidiaries, holds the majority shareholder of Zentera. Proceeds from the Series A financing will be used to develop and commercialize three cancer therapies discovered by Zentalis, in […]

OrbiMed Co-leads $20M Series A Round In Zentera Therapeutics comes from China Money Network: Primary Data for China's Primary Markets! All Rights Reserved.

Read the original article: China Money Network